HRTX Heron Therapeutics, Inc.
Heron Therapeutics, Inc. (HRTX) is expected to report earnings on November 9, 2026, before the market open. The consensus earnings estimate is a loss of $0.03 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -20.3% since its last earnings release on August 10, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Heron Therapeutics, Inc.
Heron Therapeutics Inc is a biotechnology company, developing products to address unmet medical needs. Its proprietary Biochronomer polymer-based drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals.
Sector
Healthcare
Industry
Drug Manufacturers/Other